Cargando…
Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients
Autores principales: | Zhao, Deze, He, Yi, Dian, Yating, Meng, Yu, Zeng, Furong, Deng, Guangtong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069933/ https://www.ncbi.nlm.nih.gov/pubmed/37019287 http://dx.doi.org/10.1016/j.jinf.2023.03.026 |
Ejemplares similares
-
Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023) -
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023) -
Efficacy of Paxlovid in patients with acute kidney injury who developed COVID-19
por: Cai, Hong, et al.
Publicado: (2022) -
Cardiac enzyme (troponin levels) elevation in cardiac myxomas: Is it real?
por: Alizadehasl, Azin, et al.
Publicado: (2015) -
Characteristics of pregnant patients with COVID-19 and liver injury
por: Deng, Guangtong, et al.
Publicado: (2020)